设为首页加入收藏
  • 首页
  • Start up
  • 当前位置:首页 >Start up >【】

    【】

    发布时间:2025-09-13 06:56:45 来源:都市天下脉观察 作者:Start up

    Latest

    AI

    Amazon

    Apps

    Biotech & Health

    Climate

    Cloud Computing

    Commerce

    Crypto

    Enterprise

    EVs

    Fintech

    Fundraising

    Gadgets

    Gaming

    Google

    Government & Policy

    Hardware

    Instagram

    Layoffs

    Media & Entertainment

    Meta

    Microsoft

    Privacy

    Robotics

    Security

    Social

    Space

    Startups

    TikTok

    Transportation

    Venture

    More from TechCrunch

    Staff

    Events

    Startup Battlefield

    StrictlyVC

    Newsletters

    Podcasts

    Videos

    Partner Content

    TechCrunch Brand Studio

    Crunchboard

    Contact Us

    To ensure survival, it’s essential to explore alternative funding methods rather than relying solely on classic fundraising.
    Image Credits:Getty Images
    Biotech & Health

    5 strategies for biotech startups to outlast a market downturn

    Dr. James Coates 4:00 AM PDT · March 16, 2023

    Founders in the biotech industry are no strangers to challenges. Success is impossible to come by without substantial investment, time and technical expertise. Although life science startups managed to come out relatively unscathed last year, the enduring economic climate is turning fundraising into a never-ending marathon. Inflationary market dynamics and ongoing fiscal tightening continue to pose significant risks to capital commitments. A successful raise in 2021 feels like ancient history.

    As a venture capitalist specializing in early-stage life science companies, I work with startups that have the potential to revolutionize the world against biothreats, pandemics and more. Every day I see new biotechnology that inspires my team and our investors to put capital to work. Many of these startups were well capitalized last year but are now facing difficulties as they look to raise.

    To ensure survival, it’s essential to explore alternative funding methods rather than relying solely on classic fundraising. This is especially true for biotech startups, where investment needs are higher and success timelines can be much longer.

    If you’re an entrepreneur in the biotech industry, it could be time to make practical pivots to ensure your company can thrive. Here are five strategies that could help your biotech startup navigate a cooling fundraising environment:

    1. Set lower fundraising goals

    During an economic downturn, trying to raise a large sum might not be feasible, and the time and resources you invest in fundraising could be better used on key business initiatives. By raising less, you can prioritize your survival, conserve your most valuable resource (time) and keep your focus on meeting near-term inflection points. With a smaller pool of investors, you can also maintain a stronger influence over your company’s strategy.

    2. Target experienced investors

    When raising, it’s crucial to focus on building relationships with investors who share your vision and can offer more than just capital. Investors who have experience in your industry can provide valuable guidance and connections that can help you navigate challenges and take advantage of opportunities — this type of investor is valuable in a downturn since they can advise you on technology-specific strategies.

    3. Seek partnerships

    Strategic partnerships or collaborations with other companies in your industry are also options to consider in lieu of larger rounds. Partnerships can provide access to new resources, expertise and markets that can help you grow and weather the storm.

    Techcrunch event

    Join 10k+ tech and VC leaders for growth and connections at Disrupt 2025

    Netflix, Box, a16z, ElevenLabs, Wayve, Sequoia Capital, Elad Gil — just some of the 250+ heavy hitters leading 200+ sessions designed to deliver the insights that fuel startup growth and sharpen your edge. Don’t miss the 20th anniversary of TechCrunch, and a chance to learn from the top voices in tech. Grab your ticket before Sept 26 to save up to $668.

    Join 10k+ tech and VC leaders for growth and connections at Disrupt 2025

    Netflix, Box, a16z, ElevenLabs, Wayve, Sequoia Capital, Elad Gil — just some of the 250+ heavy hitters leading 200+ sessions designed to deliver the insights that fuel startup growth and sharpen your edge. Don’t miss the 20th anniversary of TechCrunch, and a chance to learn from the top voices in tech. Grab your ticket before Sept 26 to save up to $668.

    San Francisco | October 27-29, 2025 REGISTER NOW

    4. Now is the time for grants

    During an economic downturn, competition for limited resources is heightened. With many scrambling now for nondilutive awards, it’s crucial to consider applying for grants sooner rather than later to help secure a stable financial foundation and increase your overall chances of survival. Grant writing can be time consuming, but it’s an essential step in securing external validation and government funding.

    Federal agencies have money to spend. The National Institute of Health (NIH) alone sets aside over $1.2 billion annually exclusively for small businesses. The NIH even provides budget-limit waivers for startups working in high-priority commercial health areas.

    When applying for grants, it’s crucial to be clear about your goals and go-to-market strategies. This will help you focus your efforts on key initiatives that align with your long-term vision. Also, the peer-reviewed validation from grants can boost future fundraising efforts, as it shows investors that your innovation has been vetted by external specialists.

    5. Put science before product

    As a biotech startup, you may be eager to drive product development alongside proving the underlying science of your innovation. However, this can be cost intensive, and it may not be optimal or even feasible during an economic downturn. Instead, it’s crucial to de-risk the scientific underpinning of your technology before product development. This will help you limit near-term cash burn, mitigate technical risk concerns at your next raise, increase credibility with existing partners and investors, and allow you to better time the transition from R&D to product launch. Furthermore, it can enable new external partnerships and potentially even revenue through licensing while you consider strategies for product development.

    By focusing on the science, you can also identify areas where you may be able to pivot to address immediate market needs. For example, if your technology was originally developed for a specific application but has broader implications, you may be able to pivot to meet the needs of the current market. This can also help you identify potential grant opportunities that can help you fund your research and development.

    An extension of putting science first means prioritizing expenses and optimizing cash flow. This means your company’s spending habits. Identify areas where you can cut costs without compromising on quality or progress. It may also mean reassessing your staffing needs. By being proactive, you can extend your runway and increase your chances of weathering the economic storm. This can also help you better position your company for future growth and fundraising opportunities.

    Ultimately, the key to surviving this economic climate is to remain agile and adaptable. By pivoting your strategy strategically and focusing on de-risking your scientific underpinnings, you can position your startup for long-term success. Surviving during difficult times requires patience, persistence and creativity, and by staying true to your vision and remaining flexible, you can emerge stronger on the other side.

    • 上一篇:How our startup made it through 2 recessions without relying on layoffs
    • 下一篇:Silkhaus gets $7.75M to digitize short

      相关文章

      • Accel backs startup offering 'Amazon
      • Dockhunt is a new way to discover Mac apps by looking at other people's docks
      • Spotify is finally launching support for lossless music streaming
      • Hear how to find a co
      • TechCrunch+ roundup: VC trick questions, building 3
      • Learn what it takes to turn a lab idea into a real business
      • Climate tech startups team up to decarbonize Arizona concrete plant
      • Rihanna's Savage X Fenty and a newer startup, FIT:MATCH, team up to sell better
      • Laid off from your tech job? Day One wants to give you $100,000 to start a company
      • 3 tips for CEOs planning to take parental leave

        随便看看

      • Which Instagram ad placement is more cost
      • Zarta, a creator platform focused on pay
      • Daily Crunch: Dash board temporarily suspends CEO as company investigates financial impropriety
      • Democratizing good privacy and compliance practices
      • Venture capital will soon be brimming with ghosts
      • 5 product management tips that can help startups thrive in 2023
      • Only 5 days left to save $1,000 on Disrupt passes
      • StudentFinance nabs $41M to help Europeans upskill for in
      • Ah, so SBF's FTX was all BS
      • Hear how Tonkean built its impressive board of directors on TechCrunch Live
      • Copyright © 2025 Powered by 【】,都市天下脉观察   辽ICP备198741324484号sitemap